Stock-Based Payments |
9 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Sep. 30, 2026 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-Based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Stock-Based Payments | 12. Stock-Based Payments The Company's stock-based compensation plans and related accounting are described in Note 15 to the Company's Annual Report on Form 10-K for the year ended December 31, 2025.
Indivior Long-Term Incentive Plan (LTIP) A summary of the service-based restricted stock awards and performance-based stock awards activity under the LTIP for the nine months ended September 30, 2026 is presented below (values in thousands):
Conditional awards of 2 million shares were granted in the nine months ended September 30, 2026 and 5 million in the nine months ended September 30, 2025 under the Company’s Long-Term Incentive Plan, respectively. The weighted average fair value per share of the service-based restricted stock awards granted was $33.68 for the nine months ended September 30, 2026, based on the fair market value at the date of grant. The total fair value of restricted stock awards issued was $13 million for the nine months ended September 30, 2026. The weighted average fair value per share of the performance-based stock awards granted per award was $53.87 for the nine months ended September 30, 2026, calculated using the weighted average fair market value for each of the component goals at the date of grant. Performance-based stock awards granted in the nine months ended September 30, 2026 vest based on the Company's relative total shareholder return compared to a peer group within the S&P Pharmaceutical Select Index, with vesting between 0% and 200% of target. The total fair value of performance-based stock awards issued was $85 million for the nine months ended September 30, 2026. Compensation cost for unvested service-based restricted stock awards and performance-based restricted awards not yet recognized at September 30, 2026 was $34 million and $24 million, respectively. This compensation cost will be recognized over the expected remaining weighted-average period of 2.11 years and 2.17 years for service-based restricted stock awards and performance-based stock awards, respectively.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||